Research programme: CFTR correctors - Parion Sciences
Latest Information Update: 22 Sep 2014
At a glance
- Originator Parion Sciences
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 16 Sep 2014 Preclinical trials in Cystic fibrosis in USA (PO)